Vaginal disinfection for preventing mother-to-child transmission of HIV infection

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 10, 2005, Pages

  Wiysonge, Charles Shey ^a   Shey, Muki ^a   Shang, Judith ^b   Sterne, Jonathan AC ^c   Brocklehurst, Peter ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE TRANSMISSION; DISINFECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; LAVAGE; META ANALYSIS; METHODOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; VAGINA; VIROLOGY;

DISEASE TRANSMISSION, VERTICAL; DISINFECTION; FEMALE; HIV INFECTIONS; HUMANS; IRRIGATION; LABOR, OBSTETRIC; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; RISK; VAGINA;

EID: 33644878812     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003651.pub2     Document Type: Review

References (34)

1. Gaillard P, Mwanyumba F, Verhofstede C, et al. Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombassa, Kenya. AIDS 2001;15:389-396.
2. Mandelbrot L, Msellati P, Meda N, et al. 15 Month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Sex Transm Infect 2002;78:267-270.
3. Msellati P, Meda N, Leroy V, et al. Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV-infected pregnant women in West Africa: ANRS 049b phase II randomized, double blinded placebo-controlled trial. Sex Transm Infect 1999;75:420-425.
4. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intevention to prevent HIV transmission. Lancet 1996;347:1647-1650.
5. Taha T, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997;315:216-219.
6. Autegarden JE, Pecquet C, Huet S, Bayrou O, Leynadier F. Anaphylactic shock after application of chlorhexidine to unbroken skin. Contact Dermatitis 1999;40:215.
7. Bertolli J, St Louis ME, Simonds RJ, et al. Estimating the timing of mother to child transmission of human immunodeficiency virus in a breastfeeding population in Kinshasa Zaire. J Infect Dis 1996;174:722-26.
8. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection (Cochrane Review). The Cochrane Library 2004, Issue 1.
9. Burman LG, Christensen P, Christensen K, et al. Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. The Swedish Chlorhexidine Study Group. Lancet 1992;340:65-9.
10. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:173-80.
11. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother to child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000;283:1175-82.
12. Duliege AM, Amos CI, Felton S, Biggar RJ, Goedert JJ. Birth order, delivery route and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. J Pediatr 1995;216:625-32.
13. Erny R, Siboni C. Les tampons au chlorure de benzalkonium: tolerance locale et effets sur la glaire cervicale. J Gynecol Obstet Biol Reprod 1983;12:767-774.
14. Garland JS, Alex CP, Mueller CD, Cisler-Kahill LA. Local reactions to a chlorhexidine gluconate-impregnated antimicrobial dressing in very low birth weight infants. Pediatr Infect Dis J. 1996;15:912-4.
15. Goedert JJ, Duliege AM, Amos CI, Felton S, Biggar RJ. High risk of HIV-1 infection for first-born twins. Lancet 1991;338:1471-75.
16. Harbison MA, Hammer SM. Inactivation of human immunodeficiency virus by betadine products and chlorhexidine. J Acquir Immune Defic Syndr 1989;2:16-20.
17. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. http://www.cochrane.org/resources/handbook/hbook.htm (accessed 31st March 2005). 2005.
18. Lefebvre C, Clarke MJ. Identifying randomised trials. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic reviews in health care: meta-analysis in context. London: BMJ Books, 2000.
19. Lumbiganon P, Thinkhamrop J, Thinkhamrop B, Tolosa JE. Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV) (Protocol for a Cochrane Review). The Cochrane Library 2004, Issue Issue 1.
20. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother to child HIV transmission, Bangkok, Thailand. AIDS 1999;13:407-414.
21. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:1035-9.
22. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977-87.
23. Newell ML. Mechanisms and timing of mother to child transmission of HIV-1. AIDS 1998;12:831-7.
24. Newell ML. Vertical transmission of HIV-1 infection. Trans R Soc Trop Med Hyg 2000;94:1-2.
25. Pham NH, Weiner JM, Reisner GS, Baldo BA. Anaphylaxis to chlorhexidine. Case report. Implication of immunoglobulin E antibodies and identification of an allergenic determinant. Clin Exp Allergy 2000;30:1001-7.
26. Read JS, Newell M-L. Cesarean delivery for prevention of mother-to-child transmission of HIV. Cochrane Library 2004, Issue 1.
27. Simon A, Lepage P, Karita E, et al. An assessment of the timing of mother to child transmission of human immunodeficiency virus type 1 by means of polymerase chain reaction. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:952-957.
28. Stade B, Shah V, Ohlsson A. Vaginal chlorhexidine during labour to prevent neonatal group B streptococcal infection (Protocol for a Cochrane Review). The Cochrane Library 2004, Issue 1.
29. Tholandi M, Wilkinson D, Dabis F, et al. Interventions to drecrease the risk of mother-to-child transmission of HIV-1 through breast milk (Protocol). Cochrane Library 2004, Issue 1.
30. UNAIDS/WHO. AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS. UNAIDS/01.74-WHO/CDS/CSR/NCS/2001.2. (English original, December 2001).
31. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
32. Wainberg MA, Spira B, Bleau G, et al. Inactivation of human immunodeficiency virus type 1 in tissue culture fluid and in genital secretions by the spermicide benzalkonium chloride. J Clin Microbiol 1990;28:156-158.
33. Wiysonge CSU, Brocklehurst P, Sterne JAC. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Library 2004, Issue 3.
34. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 1985;27(5):335-71.